Company: EDSA
Filing Date: 2025-12-12
Form Type: 10-K
Source: 0001171843-25-007914
Chunk: 294

Company: Edesa Biotech, Inc.
Filing Date: 2025-12-12
Form: 10-K
Item: Item 1A
Chunk 294
---
 our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets, particularly unpatented know-how, were to be obtained or independently developed by a competitor, our competitive position would be harmed.

Risks Related to Owning Our Securities

The price of our common shares may continue to be volatile.

Market prices for securities of clinical-stage pharmaceutical, biotechnology and other life sciences companies have historically been particularly volatile, and the market price of our common shares has been subject to significant fluctuations. This volatility can be exacerbated by low trading volume. Some of the factors that may cause the market price of our shares to fluctuate include:

			●

			sales or potential sales of substantial amounts of our common shares;

			●

			announcements about us or our competitors, including funding announcements, corporate or business updates, updates on manufacturing of our products, clinical trial results, regulatory approvals or new product introductions;

			●

			developments concerning our product manufacturers;

			●

			litigation and other developments relating to our licensed patents or other proprietary rights or those of our competitors;

			●

			governmental regulation and legislation;

			●

			change in securities analysts’ estimates of our performance, or failure to meet analysts’ expectations;

			●

			the terms and timing of any future collaborative, licensing or other arrangements that we may establish;

			●

			our ability to raise additional capital to carry through with our development plans and current and future operations;

			●

			the timing of achievement of, or failure to achieve, our manufacturing, pre-clinical, clinical, regulatory and other milestones, such as the commencement of clinical development, the completion of a clinical trial or the receipt of regulatory approval;

			●

			actions taken by regulatory agencies with respect to our product candidates;

			●

			uncontemplated problems in the supply of the raw materials used to produce our product candidates;

			●

			introductions or announcements of technological innovations or new products candidates by us, our potential future collaborators, or our competitors, and the timing of these introductions or announcements;

			●

			market conditions for equity investments in general, or the biotechnology or pharmaceutical industries in particular;

37

			●